February 24, 2022 02:10 PM ESTUpdated February 25, 11:05 AM
Pharma

Ab­b­Vie slams the pen­sion door to new hires as Big Phar­ma hold­outs fi­nal­ly join the mi­gra­tion to 401Ks

Paul Schloesser

Associate Editor

When As­traZeneca’s US sub­sidiary an­nounced it would be ax­ing its $1.3 bil­lion pen­sion plan a few weeks ago, the sec­ond half of End­points News‘ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times